A satirical X post saying the three major insulin manufacturers in the United States had announced 2,000%-3,000% price ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Attorney General Keith Ellison announced a settlement with Novo Nordisk that let's Minnesotans buy its insulin products for ...

Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

GLP-1 (glucagon-like peptide-1) discovered in the 1980s functions as a hormone derived from the proglucagon sequence and was found to have a transformative impact on the treatment of diabetes and ...

Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...

The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

In a bid to bring down the cost of insulin, California under Gov. Gavin Newsom inked a contract to produce the drug. It's ...

The pharmaceutical company Novo Nordisk has products sold under the Novolin brand name, and Eli Lilly ... (short-acting), NPH (intermediate-acting), or premixed NPH/regular insulin without a ...